Treatment News

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News

July 30, 2015
San Francisco Effort to Treat HIV the Day of Diagnosis is a Success
A program in San Francisco has succeeded in getting people on antiretroviral treatment the day they are diagnosed with HIV and in shortening the time until they have an undetectable viral load.
July 29, 2015
Few U.S. Youths Have HIV Under Control After Diagnosis
Just 7 percent of American youths recently diagnosed with HIV achieved an undetectable viral load during a two-year study.
Gay Meth Use Accounts For 1 in 6 New HIV Cases in Seattle Area
Crystal meth use among gay men in King County, Washington, which includes Seattle, accounts for an estimated 16 percent of new HIV transmissions.
July 28, 2015
A New Way That HIV Exploits the Immune System
HIV uses a viral protein to manipulate the immune system into suppressing natural antiviral responses so it can more easily establish an infection.
Paying South African Girls to Stay in School Doesn’t Lower HIV Rate
A program that offered cash incentives for girls living in a poor section of South Africa failed to lower the HIV infection rate among them.
July 27, 2015
In Those With HIV, Best to Treat Hep B With Two Drugs
Among HIV-positive people, it is preferable to treat hepatitis B with a two-drug regimen rather than with monotherapy.
Some PrEP Success Among White and Latino Gay Youth
Young gay and bisexual men adhered moderately well to PrEP in a recent trial, but adherence dropped over time and was very poor among black and mixed-race participants.
New HIV Med Doravirine Has Half of Sustiva’s Side Effect Rate
Merck’s next-generation NNRTI doravirine (MK-1439) suppresses HIV as well as Sustiva (efavirenz) and leads to half the rate of side effects.
July 24, 2015
Some Western Gay Men Consider Viral Load in Safer-Sex Decisions
HIV-negative gay men in Seattle as well as Australia are taking their partners’ viral load, treatment or HIV testing history into account when making decisions about condom use.
Non-Daily PrEP Likely Works For Anal, Not Necessarily Vaginal, Sex
Research into the metabolization of Truvada suggests that non-daily-dosing protocols for PrEP offer high protection against HIV infection through anal sex, while vaginal sex protection is up for debate.
Individuals’ Genes Affected HIV Vaccine Efficacy
Specific variations in personal genes among study participants played a part in determining the efficacy of an HIV vaccine that was moderately successful among Thai volunteers.
Financial Incentives Encourage African Men to Be Circumcised
Food vouchers succeed in increasing the rate of voluntary male medical circumcision (VMMC) among Kenyan men.
FDA OK’s BMS Daklinza (Daclatasvir) to Treat Hep C Genotype 3
The FDA has approved BMS's Daklinza (daclatasvir) to be used with Gilead Sciences’ Sovaldi (sofosbuvir) to treat genotype 3 of hepatitis C.
FDA Green Lights AbbVie’s Technivie for Genotype 4 of Hepatitis C
The FDA has approved AbbVie’s single-tablet combination regimen Technivie plus ribavirin to treat genotype 4 of hepatitis C virus among those without cirrhosis.
July 23, 2015
No Benefit to Treating Unconfirmed TB in Advanced HIV Cases
Providing tuberculosis treatment to people with very low CD4 counts who are just starting HIV therapy and do not have confirmed TB does not reduce the risk of death compared with giving ARVs and isoniazid preventive therapy for TB.
BMS’s Maturation Inhibitor Shows Promise
Bristol-Myers Squibb’s investigational next-generation maturation inhibitor BMS-955176 demonstrated good activity against HIV when paired with Reyataz (atazanavir) in a recent small study.
Intervention Ups Adherence to HIV Meds, Reduces Viral Load
An intervention has succeeded in motivating people with HIV to adhere to their antiretroviral regimens, ultimately reducing viral load.
July 22, 2015
HIV/Hep C Coinfection Increases Risk of Organ Rejection
People coinfected with HIV and hepatitis C are more likely to experience rejection of a transplanted liver than those who are monoinfected with either virus.
Many Cancers Are More Fatal If Someone Has HIV
People living with HIV have a greater likelihood of dying from numerous common cancers when compared with HIV-negative people.
Intercourse-Based PrEP Yields Lower Adherence Than Daily Dosing
People taking PrEP to prevent HIV tend to follow the standard daily-dosing regimen better than intermittent dosing schedules based on the timing of sexual acts.
BMS HIV Attachment Inhibitor Gets FDA Breakthrough Nod
The FDA has granted a breakthrough designation to Bristol-Myers Squibb’s investigational HIV attachment inhibitor BMS-663068.
July 21, 2015
Excellent Adherence, No New HIV Cases in Heterosexual PrEP Trial
Heterosexual participants in a study of Truvada as pre-exposure prophylaxis in Botswana apparently adhered to PrEP at very high rates, and there were no new HIV infections among them.
Cuba Is First Nation to Stop Mother-to-Child HIV Transmission
The World Health Organization has certified that Cuba has become the first country to eliminate mother-to-child transmission of HIV and syphilis.
Lack of Food Is Tied to Doing Poorly on HIV Treatment
People receiving treatment for HIV who lack sufficient food are more likely to have a detectable viral load than those who have enough to eat.
UNAIDS Goals of Testing and Treating HIV in Africa Look Achievable
International goals to test and treat high proportions of HIV-positive people by the decade’s end may be achievable in some sub-Saharan African nations.
Teen Has Viral Remission 12 Years After Stopping HIV Meds
An 18-year-old French teenager who contracted HIV from her mother has maintained control of the virus for 12 years after stopping antiretroviral treatment.
Gay and Bi Men Adhere Well to PrEP in U.S. Real-World Study
Transgender women and gay and bi men adhered at high rates to Truvada as PrEP in an American real-world study of the HIV prevention method, especially if they were at higher risk of contracting the virus.
Early HIV Treatment’s Benefits Examined More Closely
A new analysis of the major trial that provided gold-standard scientific proof supporting early treatment of HIV has illustrated in greater depth the many benefits of starting antiretrovirals soon after diagnosis and when CD4 counts are high.
July 20, 2015
New Proof That Passing On HIV While Undetectable Is Very Unlikely
A major study lends support to the belief that fully suppressing HIV through treatment makes transmitting the virus highly unlikely, at least among heterosexuals in this case.
HIV Treatment Takes Longer to Suppress Higher Viral Loads
Starting HIV treatment with a higher viral load tends to increase the time it takes to suppress the virus, extending the window of time when an individual may still be infectious. 
July 17, 2015
Non-Infectious Diseases Will Surge in Aging HIV Population
As the HIV population ages, non-communicable diseases will rise among them, in particular heart disease, as well as the use of medications for those diseases that may conflict with antiretrovirals.
July 16, 2015
Achieving Long-Term HIV Suppression Could Be Easier Than Expected
The reactivation rate of cells latently infected with HIV is much lower than previously thought, suggesting that the effort to incite long-term suppression of the virus without daily antiretroviral treatment may prove less daunting.
July 15, 2015
Prioritizing PrEP for High-Risk Kenyans Likely Spells Success
A pre-exposure prophylaxis rollout in Kenya would be the most effective if PrEP is prioritized for those at highest risk for infection.
July 14, 2015
Early HIV Treatment Especially Benefits Older People
Starting HIV treatment with a high viral load leads to a much greater reduction in death rates for people ages 45 to 65, compared with younger people with HIV
July 13, 2015
Keeping Latent HIV Dormant May Lead to Functional Cure
A natural compound has been found to significantly reduce the rate of reactivation of immune cells latently infected with HIV, suggesting a new potential route to a functional cure for the virus.
July 10, 2015
Treating HIV Low Appetite With Medical Pot Backed by Weak Science
Research supporting various uses of cannabis or cannabis-based medications provides low-quality evidence and is often beset with significant potential for bias.
July 09, 2015
Community-Based HIV Prevention Spending Reaps Huge Savings
Investing in community-based HIV prevention programs translates to a five-fold savings in avoided costs associated with treating the virus, according to a study of such programs in Ontario, Canada.
July 08, 2015
HIV Meds Should Work for Most Drug-Resistant Strains in the UK
Drug-resistant strains of HIV continue to be transmitted in the UK, but this doesn't appear likely to have a major effect on the treatment response.
Hepatitis C Has Large Impact in Sub-Saharan Africa
Sub-Saharan Africa has a high prevalence of hepatitis C, especially among HIV-positive individuals.
July 07, 2015
UNAIDS Calls for Scale-Up in Global HIV Fight
UNAIDS and the Lancet Commission have called for greater access to HIV treatment and greater prevention efforts worldwide, lest infection rates rebound.
AHF Refuses to Correct Misleading Anti-PrEP Ad
A major HIV physicians group has requested that AIDS Healthcare Foundation correct or retract a key point in the stringently anti-PrEP ad AHF placed in gay publications nationwide.
July 06, 2015
Hep C Coinfection Increases Death Risk in Drug Users With HIV
The raised risk of death resulting from injection drug use among people with HIV is substantially explained by hep C coinfection among that population.
July 03, 2015
Fact-Checking AIDS Healthcare Foundation's Latest Anti-PrEP Screed
AIDS Healthcare Foundation published an ad criticizing pre-exposure prophylaxis (PrEP) in various gay publications around the country.
July 02, 2015
Gilead Seeks FDA OK for 3rd Combo Pill With New Tenofovir
Gilead Sciences has applied to the FDA for approval of yet another combination HIV tablet including an updated version of tenofovir.
July 01, 2015
Success for Anti-HIV Gene Therapy in Mice
Researchers significantly reduced HIV levels in mice with a genetic therapy that induces immune cells to better fight the virus.
More Treatment News

Have news about HIV? Send press releases, news tips and other announcements to

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Do you regularly experience gastrointestinal issues?

Stress Test

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2015 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.